Business
Ocumetics Announces Successful Completion of Animal Studies
(TheNewswire) Calgary, A B - TheNewswire - February 13, 2023 - Ocumetic...
About this update from Ocumetics Technology Corp
[{"type":"text","content":"Ocumetics Announces Successful Completion of Animal Studies\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Calgary, A\n \n \n B\n \n \n -\n \n \n TheNewswire -\n \n \n February 13, 2023 -\n \n \n Ocumetics Technology Corp. (“\n \n \n Ocumetics\n \n \n ” or the “\n \n \n Company\n \n \n ”)\n \n \n (\n \n \n TSXV:OTC) (OTC:OTCFF)\n(FRA:2QBO)\n \n \n is pleased to announce the successful\ncompletion of its latest animal studies. “The purpose of these\nstudies was to test our latest design,” said Dr. Garth Webb,\nOcumetics’ Founder and Chief Scientific Officer.  “The lens\ndesign met and exceeded our expectations.  It is exciting to see the\ntechnology we have developed over the years coming to\nfruition.”\n \n \n \n \n Ocumetics’ Chief Medical Officer, Dr. Doyle Stulting,\nsaid “The latest design addresses the needs of ophthalmologists,\nwith the lens exiting the injector during surgery at a controlled pace\nand gently expanding to fill the capsular bag.  In addition, the new\nlens addresses all of the feedback we had received from our Medical\nAdvisory Board.”\n \n \n \n \n Dr. Mark Lee, Ocumetics’ President & CEO,\nadvises, “This is the first in a series of biocompatibility studies,\nthe second of which is scheduled to commence in March 2023.  The\nbiocompatibility studies will take 3 months to complete, which means\nwe should be able to begin our first-in-human proof of concept studies\nin July or August of 2023. We are very pleased with these latest\nresults and look forward to beginning the first human\nstudies.”\n \n \n \n \n About Ocumetics\n \n \n \n \n Ocumetics Technology Corp.\n \n \n (\n \n \n TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO)\nis a Canadian research and development company that specializes in\nadaptive intraocular lens designs.  Ocumetics is in the preclinical\nstudy stage of a game-changing technology for the ophthalmic industry.\n Ocumetics has developed an expandable intraocular lens that fits\nwithin the capsular bag following extracapsular cataract extraction.\n It is designed to allow the eye’s natural muscle activity to shift\nfocus from distance to near, potentially to eliminate the need for\ncorrective lenses.\n \n \n \n ...